GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (NAS:PODD) » Definitions » Gross Margin %

Insulet (Insulet) Gross Margin %

: 70.85% (As of Dec. 2023)
View and export this data going back to 2007. Start your Free Trial

Gross Margin % is calculated as gross profit divided by its revenue. Insulet's Gross Profit for the three months ended in Dec. 2023 was $361 Mil. Insulet's Revenue for the three months ended in Dec. 2023 was $510 Mil. Therefore, Insulet's Gross Margin % for the quarter that ended in Dec. 2023 was 70.85%.


The historical rank and industry rank for Insulet's Gross Margin % or its related term are showing as below:

PODD' s Gross Margin % Range Over the Past 10 Years
Min: 50.5   Med: 63.06   Max: 68.45
Current: 68.35


During the past 13 years, the highest Gross Margin % of Insulet was 68.45%. The lowest was 50.50%. And the median was 63.06%.

PODD's Gross Margin % is ranked better than
74.94% of 798 companies
in the Medical Devices & Instruments industry
Industry Median: 53.615 vs PODD: 68.35

Insulet had a gross margin of 70.85% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Insulet was 0.30% per year.


Insulet Gross Margin % Historical Data

The historical data trend for Insulet's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.06 64.39 68.45 61.72 68.35

Insulet Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.78 67.16 66.81 67.78 70.85

Competitive Comparison

For the Medical Devices subindustry, Insulet's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insulet Gross Margin % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Insulet's Gross Margin % falls into.



Insulet Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Insulet's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=1159.9 / 1697.1
=(Revenue - Cost of Goods Sold) / Revenue
=(1697.1 - 537.2) / 1697.1
=68.35 %

Insulet's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=361.2 / 509.8
=(Revenue - Cost of Goods Sold) / Revenue
=(509.8 - 148.6) / 509.8
=70.85 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Insulet  (NAS:PODD) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Insulet had a gross margin of 70.85% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Insulet Gross Margin % Related Terms

Thank you for viewing the detailed overview of Insulet's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Insulet (Insulet) Business Description

Traded in Other Exchanges
Address
100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.
Executives
Luciana Borio director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Shacey Petrovic officer: CCO 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Prem Singh officer: SVP, Global Operations C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
James Hollingshead director C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Wayde D. Mcmillan officer: EVP, CFO C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Mark N Field officer: SVP & Chief Technology Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Dan Manea officer: SVP, Chief HR Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTION MA 01720
Michael R Minogue director 22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Laetitia Cousin officer: SVP, Reg, Quality & Compliance C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Charles Alpuche officer: SVP, Global Manufacturing C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bret Christensen officer: SVP and CCO 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Michael P Spears officer: SVP, Quality and Regulatory C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Elizabeth H Weatherman director C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017
David A Lemoine director C/O THE L S STARRETT COMPANY, 121 CRESCENT STREET, ATHOL MA 01331
Sally Crawford director C/O HOLOGIC, INC., BEDFORD MA 01730

Insulet (Insulet) Headlines

From GuruFocus

Q2 2023 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q2 2022 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q3 2021 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q1 2023 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2021 Insulet Corp Earnings Call Transcript

By GuruFocus Research 01-23-2024